Electronic cigarettes as a harm reduction strategy among patients with COPD: protocol for an open-label two arm randomized controlled pilot trial

被引:4
|
作者
Stevens, Elizabeth R. [1 ]
Lei, Lei [1 ]
Cleland, Charles M. [1 ]
Vojjala, Mahathi [1 ]
El-Shahawy, Omar [1 ,2 ]
Berger, Kenneth I. [1 ]
Kirchner, Thomas R. [2 ]
Sherman, Scott E. [1 ]
机构
[1] New York Univ Langone Hlth, New York, NY 10016 USA
[2] New York Univ Sch Global Publ Hlth, New York, NY USA
关键词
NICOTINE DELIVERY-SYSTEMS; SMOKING-CESSATION; SELF-EFFICACY; DEPENDENCE; MOTIVATION; WITHDRAWAL; LIQUIDS; DEATHS; HEALTH;
D O I
10.1186/s13722-021-00284-0
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Smoking cessation is the most effective means of slowing the decline of lung function associated with chronic obstructive pulmonary disease (COPD). While effective smoking cessation treatments are available, they are underutilized and nearly half of people with COPD continue to smoke. By addressing both nicotine and behavioral dependence, electronic cigarettes (EC) could help people with COPD reduce the harm of combustible cigarettes (CC) through reductions in number of Cigarettes per Day (CPD) or quitting CC completely. The purpose of this pilot study is to identify barriers and facilitators to the use of and assess the preliminary effectiveness of EC as a harm reduction strategy among people with COPD. Methods: In an open-label two-arm randomized controlled trial pilot study, 60 patients identified as smokers with a COPD diagnosis via electronic health records from a large urban health center are randomized in a 1:1 ratio to either standard care [counseling +/- nicotine replacement therapy (NRT)] or counseling + EC. The NRT arm will receive nicotine patches and nicotine lozenges for 12 weeks. The EC arm will receive EC for 12 weeks. Both cohorts will receive counseling from a licensed mental health counselor. Using ecological momentary assessment, participants will report their use of CC in both arms and EC use in the EC arm daily via text message. Primary outcomes will be feasibility and acceptability of intervention, and secondary outcomes will be reduction in CPD and change in COPD symptoms as measured by COPD Assessment Tool (CAT) score at 12-weeks. EC displacement of CC. To explore attitudes towards the use of EC as a harm-reduction strategy for patients with COPD, interviews will be performed with a sample of participants from both study arms. Discussion: Despite decades of availability of smoking cessation medications, nearly half of people with COPD still smoke. This study aims to address the unmet need for feasible and effective strategies for reducing CC use among those with COPD, which has the potential to significantly improve the health of people with COPD who smoke.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Electronic cigarettes as a harm reduction strategy among patients with COPD: protocol for an open-label two arm randomized controlled pilot trial
    Elizabeth R. Stevens
    Lei Lei
    Charles M. Cleland
    Mahathi Vojjala
    Omar El-Shahawy
    Kenneth I. Berger
    Thomas R. Kirchner
    Scott E. Sherman
    [J]. Addiction Science & Clinical Practice, 17
  • [2] Acupuncture for patients with mild hypertension: study protocol of an open-label multicenter randomized controlled trial
    Juan Li
    Hui Zheng
    Ling Zhao
    Ying Li
    Yan Zhang
    Xiao-rong Chang
    Rui-hui Wang
    Jing Shi
    Jin Cui
    Yin-lan Huang
    Xiang Li
    Jie Chen
    De-hua Li
    Fan-rong Liang
    [J]. Trials, 14
  • [3] Acupuncture for patients with mild hypertension: study protocol of an open-label multicenter randomized controlled trial
    Li, Juan
    Zheng, Hui
    Zhao, Ling
    Li, Ying
    Zhang, Yan
    Chang, Xiao-rong
    Wang, Rui-hui
    Shi, Jing
    Cui, Jin
    Huang, Yin-lan
    Li, Xiang
    Chen, Jie
    Li, De-hua
    Liang, Fan-rong
    [J]. TRIALS, 2013, 14
  • [4] Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized Controlled Trial
    Kelley, John M.
    Kaptchuk, Ted J.
    Cusin, Cristina
    Lipkin, Samuel
    Fava, Maurizio
    [J]. PSYCHOTHERAPY AND PSYCHOSOMATICS, 2012, 81 (05) : 312 - 314
  • [5] Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial
    Zhou, Jian-Guo
    Zhou, Nan-Jing
    Zhang, Qiong
    Feng, Yao-yao
    Zhou, Hang
    [J]. TRIALS, 2018, 19
  • [6] The PharmNet Harm Reduction Intervention for Community Pharmacies: Protocol for a Pilot Randomized Controlled Trial
    Eldridge, Lori Ann
    Agley, Jon
    Meyerson, Beth E.
    Golzarri-Arroyo, Lilian
    [J]. JMIR RESEARCH PROTOCOLS, 2022, 11 (10):
  • [7] Open-label randomized controlled trial to compare wound dressings for patients undergoing hip and knee arthroplasty: study protocol for a randomized controlled trial
    Maria López-Parra
    Dolors Gil-Rey
    Esmeralda López-González
    Eva-Maria González-Rodríguez
    Isabel Simó-Sánchez
    Francisco Zamora-Carmona
    Lidia Roqueta-Andreu
    Marta Arizu-Puigvert
    Dolors Abril-Sabater
    Àngels Moreno-Álvarez
    Àngels López-Bonet
    Gisela López-Hidalgo
    Helena Costa-Ventura
    Laura García-Pardo
    Mireia Rico-Liberato
    Miriam García-Borràs
    Maria Teresa Arnal-Leris
    Mònica Sianes-Gallén
    Roser Vives
    [J]. Trials, 19
  • [8] RIFAXIMIN TREATMENT IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS; A MULTICENTER, OPEN-LABEL, PILOT RANDOMIZED CONTROLLED TRIAL
    Song, Do Seon
    Yang, Jin Mo
    Jung, Young Kul
    Yim, Hyung-Joon
    Kim, Hee Yeon
    Kim, Chang Wook
    Kim, Soon Sun
    Cheong, Jae Youn
    Lee, Hae Lim
    Lee, Sung Won
    Yoo, Jeong-Ju
    Kim, Sang Gyune
    Kim, Young Seok
    [J]. HEPATOLOGY, 2021, 74 : 250A - 250A
  • [9] Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial
    Jian-Guo Zhou
    Nan-Jing Zhou
    Qiong Zhang
    Yao-yao Feng
    Hang Zhou
    [J]. Trials, 19
  • [10] Chlorhexidine locking device for central line infection prevention in ICU patients: protocol for an open-label pilot and feasibility randomized controlled trial
    Zamir, Nasim
    Pook, Makena
    McDonald, Ellen
    Fox-Robichaud, Alison E.
    [J]. PILOT AND FEASIBILITY STUDIES, 2020, 6 (01)